Riding The Tailwind Of Healthtech Through The Pandemic And Beyond
COVID-19 Has Not Put The Brakes On Resurgence Of Health Care, Say Asia-Based VC Investors
VC investors and medtech strategists alike at APACMed’s 2020 virtual conference agreed that the challenges presented by COVID-19 have given healthtech a higher profile and accelerated the arrival of health system workflow improvements.
You may also be interested in...
Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.
COVID-19 business volatility continues to impact the medtech industry, but Royal Philips is targeting modest comparable sales growth for 2020 after posting quarterly growth of 10%.
Germany’s COVID-19 testing strategy now permits the use and reimbursement of coronavirus antigen tests.